Author: crauwerdink

Amyloid-targeting monoclonal antibody treatments have ushered in a new era of Alzheimer’s disease therapies after decades of research and clinical trials. A recent review published by Cochrane, a global, independent, non-profit network of researchers, professionals, patients and carers regarded as a gold standard for producing and promoting trusted, high-quality health information, has a different perspective on these therapies. The review found these treatments produce “little to no difference” in cognition and offer few benefits while increasing risks for adverse effects. Drs. Cynthia Carlsson, a clinical trialist, David Wolk, a clinician, and Henrik Zetterberg, a biomarker and disease biology expert, join the podcast to break down the review and their concerns, as well as highlight how this review could impact clinical care, research and public policy. Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, Clinical Core leader, Wisconsin Alzheimer’s Disease Research Center (ADRC), Louis A. Holland, Sr., Professor in Alzheimer’s Disease, geriatrician, University of Wisconsin (UW) School of Medicine and Public Health; David Wolk, MD, director, Penn ADRC, co-director, Penn Memory Center, co-director, Penn Institute on Aging, professor of neurology, University of Pennsylvania Perelman School of Medicine; and Henrik Zetterberg, MD, PhD, professor of neurochemistry, University of Gothenburg, visiting professor, UW–Madison and University College London, Biomarker Core co-leader, Wisconsin ADRC